{"id":98156,"date":"2019-11-05T06:22:36","date_gmt":"2019-11-05T14:22:36","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/11\/israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors"},"modified":"2019-11-05T06:22:36","modified_gmt":"2019-11-05T14:22:36","slug":"israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/11\/israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors","title":{"rendered":"Israeli team develops novel therapy to target advanced cancerous tumors"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/israeli-team-develops-novel-therapy-to-target-advanced-cancerous-tumors.jpg\"><\/a><\/p>\n<p>Holon-based cancer immunotherapy company Compugen disclosed encouraging preliminary results on Tuesday from its Phase 1 clinical trial for an antibody acting against a novel cancer drug target (PVRIG) in patients with advanced solid tumors.<\/p>\n<p>The Nasdaq and Tel Aviv-listed company, a pioneer in predictive drug target discovery, has developed innovative computational discovery platforms to identify new drug targets and subsequently produce first-in-class therapeutics. The clinical trial of the anti-PVRIG antibody, called COM701, aimed to assess the safety of escalating doses of the therapy in patients with advanced solid tumors, but also demonstrated initial signals of anti-tumor activity in the heavily pre-treated patient population enrolled in the study.<\/p>\n<p>\u201cWe are encouraged by the emerging safety profile and initial signals of anti-tumor activity of COM701,\u201d said Compugen president and CEO Dr. Anat Cohen-Dayan.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Holon-based cancer immunotherapy company Compugen disclosed encouraging preliminary results on Tuesday from its Phase 1 clinical trial for an antibody acting against a novel cancer drug target (PVRIG) in patients with advanced solid tumors. The Nasdaq and Tel Aviv-listed company, a pioneer in predictive drug target discovery, has developed innovative computational discovery platforms to identify [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1522],"tags":[],"class_list":["post-98156","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-innovation"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/98156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=98156"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/98156\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=98156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=98156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=98156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}